The day of coadministration can matter when an interacting medicine is not given continuously.
A clinical study in patients with advanced cancer compared midazolam exposure at different points in an intermittent capivasertib schedule. The observed increase was larger on one study day than another, supporting a schedule-specific CYP3A interaction assessment.
In twenty-one evaluable patients, midazolam total-exposure ratios were 1.13 on day eight and 1.75 on day twelve compared with the baseline day. The corresponding peak ratios were 1.15 and 1.25. The difference between peak and total exposure is analytically relevant. Quoting only the largest ratio without the intermittent capivasertib schedule would obscure when the observed interaction was assessed.
The group estimate came from a selected regimen and small sample. It cannot be assigned to every treatment day, dose, patient or benzodiazepine substrate. Exposure changes were not direct measurements of functional impairment.
Record the exact cycle day and recent doses when interpreting a concentration. Do not apply the largest reported ratio indiscriminately. The study supports attention to timing but cannot prove that an interaction caused a particular sedation episode without the clinical and analytical record.
Source: PMC11390765, supplied full-text paper. Findings are paraphrased; forensic implications are an interpretation.
Related: Valerian Interaction Claims Need Separate Pharmacokinetic and Sedative Evidence.